glp 1 in germany GLP-1 Weight Loss Europe: Eligibility, Costs & Access GLP-1 Receptor Agonist Market Size,

Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world

Patients lose avg 9.6 lbs in 30 days

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

in its 12th acquisition of '26, Lilly enters the psychedelics aisle w/$2.8B upfront move for AtaiBeckley GLP-1 giant, once known for its depression med Prozac, gets 3 clinical-stage brain health drug candidates follows J&J, AbbVie, Otsuka in psychedelics